Beta Bionics . Common Stock Stock Earnings Reports

Beta Bionics reported strong Q1 2026 results and raised full-year guidance. Key financials: net sales of $27.6M, up 57% year-over-year; gross margin 59.5%, up ~864 bps year-over-year; approximately $240M in cash and investments. Management attributes revenue growth to new patient starts and a growing pharmacy-installed base that delivers high‑margin recurring revenue. Pharmacy mix for new patient starts rose to the high 30s percent and is now expected to be 37%–39% for 2026. The company crossed an internal pharmacy-installed-base threshold in Q1 that makes the pharmacy channel accretive to overall gross margin and expects further margin expansion as pharmacy penetration and manufacturing scale increase. Full‑year 2026 revenue guidance was raised to $131M–$136M and gross margin guidance was raised to 57.5%–59.5%. Operating expenses rose (Q1 OpEx $40.7M) driven by salesforce expansion, R&D (Mint patch pump and bihormonal programs), and scaling G&A; management expects OpEx growth to accelerate through the year as investments continue. Company reiterated remediation work in response to an FDA warning letter—highlighting completed remediation of legacy complaints ahead of schedule—and affirmed ongoing corrective actions. Pipeline progress: Mint remains on track for an unconstrained commercial launch target by end of 2027; a Phase IIa bihormonal feasibility trial is underway with further development planned. Management also noted meaningful off‑label use in type 2 patients (~25%–30% of new starts) and expressed interest in pursuing a formal type 2 indication in the future. Overall, the story for investors is sustained commercial traction (notably via the pharmacy channel), improving unit economics and gross margins, continued investment in growth and innovation (Mint, bihormonal), a solid cash runway, and active regulatory remediation efforts.